BPTH Bio-Path Holdings
- 2.160
- +0.160+8.00%
- 2.190
- +0.030+1.38%
Bio-Path Holdings News
Express News | Bio Path Holdings Inc - Got Nasdaq Letter Granting Extension Until September 8 to Demonstrate Compliance With Stockholders' Equity Requirement
Why Bio-Path Stock Is Climbing Today
Bio-Path Holdings, Inc. (NASDAQ:BPTH) shares are trading higher Friday after the company announced interim results from its Phase 2 study of prexigebersen in combination with decitabine and venetoclax
Market-Moving News for June 14th
ADBE: 16% | Adobe shares are trading higher following better-than-expected Q2 earnings and strong guidance.BPTH: 46% | Bio-Path Holdings shares are trading higher after the company announced interim r
12 Health Care Stocks Moving In Friday's Pre-Market Session
GainersAinos (NASDAQ:AIMD) stock rose 54.8% to $1.27 during Friday's pre-market session. The market value of their outstanding shares is at $8.2 million. Longeveron (NASDAQ:LGVN) shares moved upwards
Express News | Bio-Path Holdings Shares Are Trading Higher After the Company Announced Interim Results From Its Phase 2 Study of Prexigebersen in Combination With Decitabine and Venetoclax for the Treatment of Acute Myeloid Leukemia
Bio-Path Holdings Reveals Interim Results From Phase 2 Study Of Prexigebersen In Combination With Decitabine And Venetoclax For Treatment Of Acute Myeloid Leukemia
The company presented interim results from the Company's Phase 2 study of prexigebersen (BP1001) in combination with decitabine and venetoclax for the treatment of acute myeloid leukemia (AML) in a poster presentation at 2024 European Hematology Association (EHA) Congress, on June 14, 2024 in Madrid, Spain.
Bio-Path Holdings Presents Data From Ongoing Phase 2 Combination Study of Prexigebersen for Treatment of Acute Myeloid Leukemia at European Hematology Association Congress
HOUSTON, June 14, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize liposomal delivery and antisense technology to develop a portfolio
Bio-Path Files to Sell 5.56M Common Stock, Warrants
Express News | Bio Path Holdings Inc Files Prospectus Related to Offering of up to 5.6 Mln Shares of Common Stock by Selling Stockholders - SEC Filing
Express News | Bio-Path Holdings Announces Closing of $4.0 Million Private Placement Priced at-the-Market Under Nasdaq Rules
Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q1 24
Express News | Bio-Path Holdings Shares Are Trading Lower After the Company Announced a $4 Million Private Placement
Bio-Path Holdings Announces $4M Private Placement Of 1,809,955 Shares Of Its Common Stock, Series A Warrants To Purchase Up To 1,809,955 Shares Of Common Stock And Short-Term Series B Warrants To Purchase Up To 1,809,955 Shares Of Common Stock At A...
Bio-Path Holdings Announces $4M Private Placement Of 1,809,955 Shares Of Its Common Stock, Series A Warrants To Purchase Up To 1,809,955 Shares Of Common Stock And Short-Term Series B Warrants To Purc
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
GainersAnnexon (NASDAQ:ANNX) shares increased by 57.2% to $7.2 during Tuesday's pre-market session. The market value of their outstanding shares is at $665.3 million. Fresh2 Group (NASDAQ:FRES) shares
Express News | Bio-Path Holdings Announces $4.0 Million Private Placement Priced at-the-Market Under Nasdaq Rules
Sector Update: Health Care Stocks Gain Late Afternoon
Health care stocks rose late Monday afternoon with the NYSE Health Care Index adding 0.5% and the Health Care Select Sector SPDR Fund (XLV) up 0.6%. The iShares Biotechnology ETF (IBB) advanced 1.1%.
Why Science Applications International Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of Science Applications International Corporation (NASDAQ:SAIC) declined 11% to $119.91 following first-quarter results.SAIC reported a 9% revenue decline year over year in the fiscal first qua
Top Midday Gainers
Structure Therapeutics (GPCR) shares soared about 78% amid heavy trading after the company reported Monday positive 12-week topline obesity data from its phase 2a trial of GSBR-1290, with results show
What's Going On With Bio-Path Stock?
Bio-Path Holdings, Inc. (NASDAQ:BPTH) shares are trading higher Monday after the company announced the presentation of interim results from its Phase 2 study of prexigebersen (BP1001) in combination w
Express News | Bio-Path Shares Are Trading Higher After the Company Announced the Presentation of Data From Its Ongoing Phase 2 Combination Study of Prexigebersen for the Treatment of Acute Myeloid Leukemia at the ASCO Annual Meeting
Analysis
Price Target
No Data
